Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing
Previous Study | Return to List | Next Study

Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03422432
Recruitment Status : Recruiting
First Posted : February 5, 2018
Last Update Posted : February 5, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Centre, Singapore

Brief Summary:

The study investigators hypothesize that prophylactic HIPEC is feasible and well tolerated in patients with colorectal cancers with high-risk of developing peritoneal recurrence.

The aim of the pilot study is to test the feasibility of performing prophylactic HIPEC for colorectal cancer patients at high-risk of developing peritoneal recurrence in our institution, and determine the morbidity associated with such a procedure.

Patients with high-risk of developing peritoneal recurrence are defined as patients with

  1. tumours involving the serosa and adjacent viscera (i.e. T4 cancers)
  2. krukenburg tumours (i.e. ovarian metastases)
  3. perforated tumours
  4. positive peritoneal fluid cytology
  5. minimal synchronous PC (nodules <1cm in the omentum and/or close to the primary tumour).

The study investigators plan to assess feasibility according to

  1. The number of patients completing the treatment
  2. Time to adjuvant systemic chemotherapy, to evaluate if there is delay to adjuvant treatment

Morbidity will be measured according to the Clavien-Dindo Classification, and graded according to low versus high grade morbidity.

If prophylactic HIPEC is shown to be feasible, with acceptable morbidity, the investigators aim to carry out a randomized controlled trial to determine the effectiveness of prophylactic HIPEC in preventing the development of peritoneal metastases in patients with colorectal cancer at high risk of peritoneal recurrence.


Condition or disease Intervention/treatment Phase
Colorectal Cancer Peritoneal Metastases Procedure: HIPEC Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Pilot Study: Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Cancers at High Risk of Developing Peritoneal Metastases
Actual Study Start Date : September 28, 2017
Estimated Primary Completion Date : May 31, 2018
Estimated Study Completion Date : May 31, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
Patients are identified pre-operatively on radiological imaging. Prophylactic HIPEC will be delivered intra-operatively, immediately after the resection of the primary tumour, and only if the patient is deemed well enough to receive the HIPEC.
Procedure: HIPEC
All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.

Experimental: Group 2
Patients are identified post-operative based on histological findings. They will be counselled to receive prophylactic HIPEC only. If peritoneal nodules are found during surgery, these patients will be excluded from the study.
Procedure: HIPEC
All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.




Primary Outcome Measures :
  1. The number of patients completing the treatment [ Time Frame: From start to end of study, approximately 1 year ]
  2. Time to adjuvant systemic chemotherapy [ Time Frame: 3 months from date of surgery ]
    To evaluate if there is delay to adjuvant treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Two groups of patients may be enrolled:

Group 1 patients are identified pre-operatively on radiological imaging, while Group 2 patients are identified post-operative based on histological findings.

All patients diagnosed with adenocarcinoma of the colon and rectum, and either one of the five following risk factors for peritoneal metastases will be considered for inclusion:

  1. T4 tumours - in Group 1, this would consist of obvious clinical T4 stage based on preoperative imaging, and in Group 2, this would be on pathological confirmation of a T4 tumour.
  2. Krukenburg tumours - Unilateral or bilateral ovarian masses seen on preoperative imaging
  3. Perforated tumours - in Group 1, this would consist of patients presenting with perforation on preoperative imaging, and undergoing curative resection, and in Group 2, this would be on pathological or intra-operative confirmation of a perforated tumour.
  4. Limited synchronous peritoneal metastases (peritoneal nodules <1cm in the omentum and/or close to the tumour). Patients with limited peritoneal disease in close proximity to the primary tumour, that may be removed enbloc with the primary resection can be included, but patients with more extensive peritoneal disease and those with extra-peritoneal metastases i.e. liver and/or lung metastases will be excluded from the study.
  5. Positive cytology in Group 2 patients

Other inclusion criteria:

  1. Patients must be between the ages of 21 and 75 years
  2. Patients must be in a stable clinical condition to undergo simultaneous HIPEC after the primary curative colorectal resection
  3. Patients must have an ECOG performance status 0 or 1
  4. Patients must have normal organ and marrow function as defined below:

i. Absolute neutrophil count > 1.5 x 109/L ii. Platelets > 100 x 109/L iii. Haemoglobin > 9.0g/dl iv. Total bilirubin ≤1.5 x ULN v. AST(SGOT)/ALT(SGPT) < 3 X institutional ULN vi. Creatinine ≤1.5 x upper limit of normal (ULN) OR vii. Creatinine clearance ≥60 mL/min for patients with creatinine levels >1.5 x institutional UL e. Patients must have a normal coagulation profile f. Patients must give written informed consent

Exclusion Criteria:

  1. Patients who are not fit to give consent for the procedure
  2. Patients who are not fit to undergo surgery
  3. Patients who are pregnant
  4. Patients who have extensive synchronous peritoneal disease
  5. Patients with extra-peritoneal metastases i.e. liver and/or lung metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03422432


Contacts
Layout table for location contacts
Contact: Grace Tan, MD +65 6436 8000 grace.tan.h.c@singhealth.com.sg

Locations
Layout table for location information
Singapore
National Cancer Centre Singapore Recruiting
Singapore, Singapore, 169610
Contact: Grace Tan, MD    +65 6436 8000    grace.tan.h.c@singhealth.com.sg   
Principal Investigator: Grace Tan, MD         
Sponsors and Collaborators
National Cancer Centre, Singapore
Investigators
Layout table for investigator information
Principal Investigator: Grace Tan, MD National Cancer Centre, Singapore

Layout table for additonal information
Responsible Party: National Cancer Centre, Singapore
ClinicalTrials.gov Identifier: NCT03422432     History of Changes
Other Study ID Numbers: 2017/2402/B
First Posted: February 5, 2018    Key Record Dates
Last Update Posted: February 5, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes